Advanced in Non-Small Cell Lung Cancer (NSCLC)

Dr. Suzanne M. Cole

Hematology Oncology | Hematology | Oncology
University Of Texas Southwestern Medical Center At Dallas
3030 Waterview Pkwy, 
Richardson, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Advanced in Non-Small Cell Lung Cancer (NSCLC)
University Of Texas Southwestern Medical Center At Dallas
3030 Waterview Pkwy, 
Richardson, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Suzanne Cole is a Hematologist Oncology specialist and a Hematologist in Richardson, Texas. Dr. Cole is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), Thrombectomy, and Nephrectomy.

Her clinical research consists of co-authoring 32 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles and participated in 1 clinical trial in the study of Non-Small Cell Lung Cancer (NSCLC).

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
UT Of Texas Southwestern University Hospital - William P. Clements Jr.
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
3030 Waterview Pkwy, Richardson, TX 75080

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Intervention Type: Other
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: a Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: a Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab
Study Phase: Phase 3
A Window-of-opportunity Trial of Abemaciclib Followed by Radical Cystectomy in Patients With Platinum-ineligible Urothelial Carcinoma to Evaluate CDK4/6-dependent Phosphorylation of Pocket Proteins and Clonal Evolution Dynamics
A Window-of-opportunity Trial of Abemaciclib Followed by Radical Cystectomy in Patients With Platinum-ineligible Urothelial Carcinoma to Evaluate CDK4/6-dependent Phosphorylation of Pocket Proteins and Clonal Evolution Dynamics
Enrollment Status: Active_not_recruiting
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drug: Abemaciclib
Study Phase: Early Phase 1
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 3
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer (CIRTiN-BC): A Phase II, Single-Arm Trial
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer (CIRTiN-BC): A Phase II, Single-Arm Trial
Enrollment Status: Terminated
Publish Date: February 06, 2024
Intervention Type: Radiation
Study Phase: Not Applicable
View 9 Less Clinical Trials

32 Total Publications

Innate and adaptive immune features associated with immune-related adverse events.
Innate and adaptive immune features associated with immune-related adverse events.
Journal: Journal for immunotherapy of cancer
Published: July 30, 2025
Similar Doctors
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. David E. Gerber
Oncology | Hematology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. David E. Gerber
Oncology | Hematology

University Of Texas Southwestern Medical Center At Dallas

6201 Harry Hines Blvd, Dermatology, 
Dallas, TX 
 (13.3 miles away)
214-645-2400
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Gerber is an Oncologist and a Hematologist in Dallas, Texas. Dr. Gerber is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Endoscopy.

John D. Minna
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. John D. Minna
Oncology | Hematology Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. John D. Minna
Oncology | Hematology Oncology
5323 Harry Hines Blvd, 
Dallas, TX 
 (13.6 miles away)
214-645-8600
Languages Spoken:
English
See accepted insurances

John Minna is an Oncologist and a Hematologist Oncology provider in Dallas, Texas. Dr. Minna is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC).

Jonathan E. Dowell
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Jonathan E. Dowell
Hematology Oncology | Hematology | Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Jonathan E. Dowell
Hematology Oncology | Hematology | Oncology

University Of Texas Southwestern Medical Center At Dallas

2201 Inwood Rd, 
Dallas, TX 
 (13.1 miles away)
214-645-2700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jonathan Dowell is a Hematologist Oncology specialist and a Hematologist in Dallas, Texas. Dr. Dowell is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, and EGFR Positive Lung Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cole's expertise for a condition
ConditionClose
    View All 13 Distinguished Conditions
    View All 47 Advanced Conditions
    View All 131 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile